Thierry Cousin

Title: Thierry Cousin: Innovator in Immune Thrombocytopenia Treatment

Introduction

Thierry Cousin is a notable inventor based in Bordeaux, France. He has made significant contributions to the field of medicine, particularly in the treatment of immune thrombocytopenia (ITP). His innovative approach has the potential to improve the lives of many patients diagnosed with this condition.

Latest Patents

Thierry Cousin holds a patent for "Compositions and methods for treating immune thrombocytopenia." This patent discloses a method for treating human subjects diagnosed with ITP. The method involves administering a human neonatal Fc receptor (hFcRn) antagonist, which may be combined with standard-of-care ITP treatments. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). The standard treatments may include corticosteroids, immunosuppressants, and thrombopoietin receptor (TPO-R) agonists. He has 1 patent to his name.

Career Highlights

Thierry Cousin is associated with Argenx BV, a company known for its innovative therapies. His work at Argenx has focused on developing treatments that address unmet medical needs, particularly in the area of autoimmune diseases.

Collaborations

Thierry has collaborated with notable colleagues such as Hans De Haard and Peter Ulrichts. Their combined expertise has contributed to advancements in therapeutic strategies for ITP.

Conclusion

In summary, Thierry Cousin is a prominent inventor whose work in the treatment of immune thrombocytopenia showcases his commitment to advancing medical science. His innovative methods and collaborations highlight the importance of research in improving patient outcomes.